Last updated on October 2018

A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously Treated Solid Tumors and Hematologic Malignancies


Brief description of study

This is an open-label, Phase I, dose-escalation study to determine the maximum tolerated dose (MTD) and/or recommended phase two dose (RPTD), and evaluate the safety, efficacy, and pharmacokinetic (PK) profile of ABBV-621 for participants with previously treated solid tumors or hematologic malignancies.

Clinical Study Identifier: NCT03082209

Contact Investigators or Research Sites near you

Start Over

ABBVIE CALL CENTER

Ingalls Memorial Hosp /ID# 171221
Harvey, IL United States
  Connect »